5 Key Potential Catalysts Pin Past Champ (Nasdaq: INBS) To Our Watchlist (Tiny Float)

Now on radar... Here's a past champ in our crosshairs.

*Sponsored 5 Key Potential Catalysts Pin Past Champ (Nasdaq: INBS) To Our Watchlist (Tiny Float) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* December 17th Greetings, Friend! Now on radar... Here's a past champ in our crosshairs. Brought into focus back a over the summer, it originally popped from an open of $1.28 to a high of $2.25 in the short term. That run of approximately 74% showed how explosive this under-the-radar Nasdaq profile can be. And after a recent reverse split that has dropped this profile's float below 1Mn shares, this Nasdaq profile now tops our watchlist. Consider taking a look at: Intelligent Bio Solutions Inc. (Nasdaq: INBS) Intelligent Bio Solutions Inc. is rapidly emerging as a leader in the medical technology sector, pioneering non-invasive, real-time point-of-care testing solutions that are reshaping how drug screening and diagnostics are conducted worldwide. With a focus on pain-free, accessible, and accurate testing, the company is positioned at the forefront of a global movement toward more humane and efficient healthcare technologies. Company Overview Founded in 2016 and headquartered in New York, Intelligent Bio Solutions Inc. is committed to leveraging advanced technology to develop transformative solutions that improve quality of life. The company’s mission is to redefine the approach to testing by delivering pain-free, accessible solutions that drive transformative change across healthcare and workplace safety. Core Technologies and Products Intelligent Fingerprinting Drug Testing Solution At the heart of INBS’s innovation is the Intelligent Fingerprinting Drug Testing Solution. This system utilizes a patented technology that analyzes sweat collected from the fingertips to detect recent drug use-including cann-a-bis, co-caine, o-piate-s, and me-thamp-heta-mine-within the preceding 16–24 hours. The process is non-invasive, requiring less than a minute for sample collection and delivering results in under ten minutes. Key advantages include: Dignified, Non-Invasive Collection: No need for blood, urine, or saliva samples, reducing discomfort and privacy concerns. Rapid Results: Enables timely decision-making in workplace, clinical, and law enforcement settings. Portability and Ease of Use: Designed for use in the field, workplaces, and clinics, with minimal training required. Hygienic and Cost-Effective: Reduces biohazard risks and maintenance costs, with annual calibration sufficing for ongoing use. Regulatory Milestones And U.S. Market Entry A significant milestone was achieved with the submission of the FDA 510(k) pre-market notification for the Intelligent Fingerprinting Drug Screening System in December 2024. The company’s clinical studies have demonstrated high sensitivity, specificity, and usability, with performance data showing 94.1% accuracy and pharmacokinetic studies confirming the reliability of fingerprint sweat as a matrix for drug detection. INBS is on track for a planned expansion into the multi-Bn dollar U.S. market in 2026, targeting a region that accounts for approximately 28% of the global drug screening market. The rising rates of drug positivity in the U.S. workforce-particularly in safety-sensitive industries-underscore the urgent need for effective, rapid, and non-invasive testing solutions like those offered by INBS. Intellectual Property and Competitive Position INBS’s technology is protected by a robust intellectual property portfolio, including six U.S. patents covering the lateral flow test strip, sample collection cartridge, cartridge housing, and buffer clip design. This IP protection strengthens the company’s competitive position as it prepares for broader commercialization and future product development. Market Opp. And Future Outlook Why Take A Closer Look? Intelligent Bio Solutions Inc. stands out for several compelling reasons: Innovative, Patented Technology: Non-invasive, rapid, and highly accurate testing solutions with strong IP protection. Proven Market Acceptance: Operational in at least 19 countries with a growing base of over 480 customer accounts. Strong Financial Trajectory: Demonstrated revenue and margin growth, with a scalable, recurring revenue model. Strategic Global Expansion: Active in high-growth markets and sectors, with multilingual capabilities and key partnerships. Clear Path to U.S. Market: On track for potential FDA clearance and entry into the world’s largest drug screening market in 2025. Vision for Broader Diagnostics: Versatile biosensor platform poised for future applications in clinical diagnostics. ----- Five (Nasdaq: INBS) Potential Catalysts To Consider #1. A Low Float - INBS has a very low float of roughly 868.43k shares. This means volatility potential may be heightened on a daily basis. #2. An Analyst $12 Target - As of December 17th, Ladenburg Thalmann Co. Inc. was reporting a $12 target on INBS. From its closing valuation on Wednesday, that target is suggesting INBS to have over 100% potential upside. #3. Intelligent Bio Solutions Achieves Record Growth Through Strategic Expansion Success. Intelligent Bio Solutions delivered record first-quarter fiscal 2026 revenue of $1.11Mn, up 32% sequentially and 28% year-over-year, fueled by rising consumable cartridge sales and a broadened customer base. Gross pro-fit margins surged 690 basis points to 46.6%, reflecting higher efficiency and greater sales from high-margin products. The Company’s innovative non-invasive testing solutions gained strong global traction, validating its consumable-driven strategy. CEO Harry Simeonidis emphasized that the momentum and expanding pro-fit-ability position INBS for sustained growth and successful future U.S. market entry. #4. Intelligent Bio Solutions Expands Customer Base Demonstrating Strong Growth And Confidence. Intelligent Bio Solutions added 33 new customer accounts in fiscal Q1 2026, a 50% year-over-year increase, boosting total active accounts to over 480. This growth highlights rising adoption of the company’s non-invasive drug testing technology across key sectors—maritime, logistics, electronics, construction, and newly entered government administration. The expansion underscores strong customer trust and broadening market reach.  CEO Harry Simeonidis noted that this momentum validates INBS’s value proposition and positions the company for continued revenue growth and long-term market leadership through proven operational and compliance benefits.  #5. Intelligent Bio Solutions Secures Major UK Contract Strengthening Global Market Presence. Intelligent Bio Solutions secured a significant UK contract with a multinational industrial service provider employing over 30,000 staff globally and 3,000 in the UK and Ireland. The deal showcases rapid adoption of INBS’s non-invasive drug testing technology across high-volume, safety-critical industries like energy, defense, and nuclear.  CEO Harry Simeonidis emphasized that this partnership reinforces market trust in INBS’s innovative solutions, validates its value-driven approach, and boosts recurring consumables revenue potential. The contract marks another milestone in the company’s expanding global footprint and accelerating commercial momentum. ----- Now underway: coverage is officially kicked-off again on Intelligent Bio Solutions Inc. (Nasdaq: INBS). Be on watch for updates coming shortly. Talk soon. All the best, Dane James Editor Market Pulse Today Sources: INBS Website INBS Presentation (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 12/17/2025 and ending on 12/18/2025 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/inbs-kxhqr/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice